Synvista Therapeutics, Inc. (SYNI)

Market Cap	3.00 -100.0%
Revenue (ttm)	54.73K -51.6%
Net Income	-19.80M
EPS	-7.66
Shares Out	2.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	260
Average Volume	886
Open	0.0000
Previous Close	0.0000
Day's Range	0.0000 - 0.0000
52-Week Range	0.0000 - 0.0000
Beta	34.13
RSI	41.93
Earnings Date	n/a

About Synvista Therapeutics

Synvista Therapeutics, Inc., a product-based biopharmaceutical company, develops diagnostic tests and drugs to identify and treat diabetic patients at high risk for the development of cardiovascular disease. The company’s products include ALT-2074, a glutathione peroxidase mimetic in Phase II clinical trials for the treatment of diabetic patients with Hp2-2; and Alagebrium chloride or alagebrium, an Advanced Glycation End-product Crosslink Breaker in Phase II clinical trials for the treatment of diastolic heart failure and diabetic nephropathy....

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1986
• Employees: 9
• Stock Exchange: OTCMKTS
• Ticker Symbol: SYNI

Financial Performance

In 2007, Synvista Therapeutics's revenue was $51,066, a decrease of -17.73% compared to the previous year's $62,069. Losses were -$19.95 million, -1.90% less than in 2006.